Cadrenal Therapeutics (CVKD) investor relations material

Company overview and market focus

• Focuses on developing novel anticoagulant drugs targeting high-risk and orphan indications within the $38B global oral anticoagulation market, specifically a $2B U.S. segment.

• Avoids markets dominated by direct oral anticoagulants, instead addressing end-stage kidney disease, left ventricular assist devices, and mechanical heart valves.

• Lead products are tecarfarin, a next-generation vitamin K antagonist, and frunexian, an IV Factor XIa inhibitor for acute care.

Tecarfarin program updates

• Tecarfarin is not metabolized by the hepatic cytochrome P450 system, offering more predictable drug levels and fewer drug-drug interactions.

• Holds orphan drug and fast track designations for ESKD, AFib, and LVADs, with seven years of exclusivity post-approval.

• Phase II/III ready, with drug product manufactured and a phase II study in dialysis patients planned for early 2026.

• EmbraceAC study showed tecarfarin matched or outperformed intensively managed warfarin, especially in patients with abnormal metabolism or drug interactions.

• Demonstrated stable drug levels in severe kidney disease, unlike warfarin, supporting its use in high-risk populations.

Frunexian acquisition and acute care focus

• Frunexian is a fast-on, fast-off IV Factor XIa inhibitor, uniquely positioned for acute care applications such as complex cardiac surgery.

• Only Factor XIa inhibitor in development for acute care, with two completed phase I studies.

• 2026 goals include formulation optimization and advancing towards clinical trials for complex cardiac surgery.